Delving into the Latest Updates on Cilastatin Sodium/Imipenem/Relebactam with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Cilastatin/imipenem/relebactam, Cilastatin/relebactam/imipenem, IMI/REL

+ [15]

Target

PBPs x β-lactamase

Action

inhibitors

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), β-lactamase inhibitors(Beta Lactamase inhibitors)

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesUrogenital Diseases+ [1]

Active Indication

Infectious DiseasesHospital acquired bacterial pneumoniaVentilator associated bacterial pneumonia+ [7]

Inactive Indication

Carbapenem Resistant Bacterial InfectionFebrile NeutropeniaHematologic Neoplasms+ [1]

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

Merck Sharp & Dohme BV

Merck Sharp & Dohme Corp.

Merck Sharp & Dohme (UK) Ltd.

+ [2]

Inactive Organization

Merck Sharp & Dohme LLC

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (16 Jul 2019),

Complicated intra-abdominal infectionComplicated urinary tract infectionGram-Negative Bacterial Infections+ [1]

RegulationPriority Review (United States), Fast Track (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC12H19N3O5S

InChIKeyGSOSVVULSKVSLQ-JJVRHELESA-N

CAS Registry74431-23-5

View All Structures (3)

This is a multicenter stepped-wedge cluster randomized trial, conducted over a 2-year period at three hospitals. The trial is structured into four phases, each lasting six months. During phase 1 (pre-rollout), all hospitals will use standard antibiotic prophylaxis for all patients. In each of phases 2 to 4, one hospital will switch to targeted antibiotic prophylaxis, so that by phase 4 all hospitals will be using it. The order in which hospitals switch is determined by computer-generated randomization performed centrally by an independent statistician, ensuring each hospital has an equal chance of switching at any given phase and minimizing selection bias.
The goal of this clinical trial is to learn whether targeted antibiotic prophylaxis works better than standard antibiotic prophylaxis at preventing infections in liver transplant patients who carry resistant bacteria called CPE (carbapenemase-producing Enterobacterales). It will also learn about the effects of these antibiotics on gut bacteria.
The main questions it aims to answer are:
* Does targeted antibiotic prophylaxis reduce the number of CPE infections occurring in the first two weeks after liver transplant, compared to standard prophylaxis?
* How do targeted and standard antibiotic prophylaxis affect the gut microbiome after transplant?
* Is there a link between achieving optimal antibiotic blood levels and the risk of developing an infection after transplant?
Researchers will compare targeted antibiotic prophylaxis (chosen based on the specific bacteria each patient carries) to standard antibiotic prophylaxis (used routinely at each hospital) to see which approach better prevents infection.
This study does not involve the administration of any drugs or instrumental examinations beyond those already part of standard clinical care at each center. However, additional blood tests will be performed by collecting one extra blood sample (and a bile sample, if the patient has a Kehr's tube, which is a drain placed in the bile duct after surgery) during blood draws already scheduled as part of routine clinical practice, in order to measure drug levels in the blood. Stool samples will also be collected specifically for the study to investigate the gut microbiome.

Start Date01 Oct 2026

Sponsor / Collaborator

IRCCS Azienda Ospedaliero-Universitaria di Bologna

NCT05561764

/ TerminatedPhase 4IIT

A Multicenter, Open-label Study to Determine the Pharmacokinetics, Safety, and Outcomes of Imipenem/Cilastatin/Relebactam During Treatment of Acute Pulmonary Exacerbations in Adolescent and Adult Patients With Cystic Fibrosis

There is established evidence that patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Imipenem/cilastatin/relebactam is a novel broad spectrum intravenous beta-lactam/beta-lactamase inhibitor combination antibiotic with potent activity against multidrug resistant Gram-negative bacteria, including imipenem non-susceptible Pseudomonas aeruginosa. Relebactam has also been shown to restore imipenem activity in Burkholderia cepacia complex, a group of opportunistic multidrug resistant pathogens that commonly infect patients with CF. This study will determine the pharmacokinetics and tolerability of imipenem/cilastatin/relebactam in 16 adolescent and adult patients with CF acute pulmonary exacerbations at one of seven participating hospitals in the US, with exploratory aim of reporting relative percent increase in FEV1 from pre- to post-treatment and return to baseline FEV1 after treatment with imipenem/cilastatin/relebactam for acute pulmonary exacerbations due to P. aeruginosa in patients with CF. Patients will receive a 10-14 day course of imipenem/cilastatin/relebactam, dosed according to renal function every 6 hours over 30 mins, with or without adjunctive aminoglycoside or fluoroquinolone therapy per local hospital guidelines. Blood will be sampled during one dosing interval at steady-state (i.e. after at least 3 doses) to determine concentrations and pharmacokinetics of imipenem and relebactam. Relative change in pulmonary function will be assessed two weeks after end of therapy. Safety and tolerability will be assessed throughout the duration of the study.

Start Date03 Jan 2023

Sponsor / Collaborator

Hartford Hospital

[+6]

NCT05146154

/ WithdrawnPhase 4IIT

Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients

This study is an open-label, multiple-dose pharmacokinetic study of imipenem-relebactam conducted in 12 non-infected, obese ICU patients.

Start Date01 Jan 2023

Sponsor / Collaborator

University of Illinois

[+1]

100 Clinical Results associated with Cilastatin Sodium/Imipenem/Relebactam

Login to view more data

100 Translational Medicine associated with Cilastatin Sodium/Imipenem/Relebactam

Login to view more data

100 Patents (Medical) associated with Cilastatin Sodium/Imipenem/Relebactam

Login to view more data

33

Literatures (Medical) associated with Cilastatin Sodium/Imipenem/Relebactam

01 Aug 2025·INFECTION

Comparison of the in vitro activities and resistance mechanisms against imipenem–relebactam and ceftazidime–avibactam in clinical KPC-producing Klebsiella pneumoniae isolated in China

Article

Author: Guo, Yingyi ; Zhuo, Chao ; Li, Jiahui ; Zhuo, Chuyue ; Chen, Jiakang ; Lin, Zhiwei ; Yao, Likang ; Yang, Xu ; Xiao, Shunian ; He, Nanhao ; Wang, Yijing ; Wang, Jiong ; Lin, Yexin ; Zhang, Yan

BACKGROUND:

Ceftazidime-avibactam (CAZ-AVI) and imipenem-relebactam (IMI-REL) are both antibiotics with promising prospects for treating Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp) infections. However, differences in the in vitro activities and resistance mechanisms to CAZ-AVI and IMI-REL in clinical KPC-Kps have not been described.

METHODS:

In this study, KPC-Kp isolates from hospitalized patients in China were collected and subjected to antimicrobial susceptibility testing of IMI-REL and CAZ-AVI using the broth microdilution method. Whole-genome sequencing (WGS) and functional validation of mutations were performed on resistant strains, and RT-qPCR was used to determine the expression levels of bla_KPC.

RESULTS:

The results showed that 21 (2.7%) of 782 clinical KPC-Kp strains were CAZ-AVI-resistant, 6 (0.8%) of 782 strains were IMI-REL-resistant, and 5 strains among them were resistant to both CAZ-AVI and IMI-REL. Strains resistant to both CAZ-AVI and IMI-REL can be effectively inhibited by tigecycline and polymyxin B. WGS and complementation experiments showed that KPC mutations are linked to high-level resistance to CAZ-AVI; while OmpK36 mutations may be the vital mechanism of IMI-REL resistance, confers resistance to CAZ-AVI simultaneously. Furthermore, RT-qPCR indicated that elevated bla_KPC expression may play an important role in both CAZ-AVI and IMI-REL resistance.

CONCLUSIONS:

In summary, this study suggested that IMI-REL may have superior inhibitory effects in vitro on KPC-Kps than CAZ-AVI, and described the differences in resistance mechanisms between the two antibiotics.

01 Jun 2025·Infectious Diseases Now

Antimicrobial activity of new anti-Pseudomonas beta-lactam-beta-lactamase inhibitors against Pseudomonas aeruginosa respiratory isolates recovered during the study for Monitoring Antimicrobial Resistance Trends (SMART) program in France (2016–2022)

Article

Author: Pailhoriès, Hélène ; Eckert, Catherine ; Pierrat, Gautier ; Woerther, Paul-Louis ; Corvec, Stéphane ; Kempf, Marie ; Zins, Charlie ; Bourge, Xavier ; Boyer, Sophie ; Dahyot, Sandrine ; Chenouard, Rachel

OBJECTIVES:

To assess the susceptibility of ceftolozane/tazobactam (C/T) and comparators to Pseudomonas aeruginosa isolates recovered from respiratory-tract-infections (RTI) between 2016-2022 in the French SMART study.

METHODS:

Antibiotic susceptibility testing and minimum inhibitory concentrations (MICs) of 717 P.aeruginosa isolates collected in five French hospitals were determined and interpreted according to the EUCAST-2022 guidelines. P. aeruginosa isolates resistant (R) to imipenem and/or C/T were screened by PCR for extended-spectrum-β-lactamases (ESBLs), AmpC and carbapenemase genes. The identified genes were sequenced and the variants determined.

RESULTS:

All in all, 96.5 % of P. aeruginosa isolates were susceptible to C/T, comparable to the susceptibilities of meropenem-vaborbactam (MVB = 96.5 %), imipenem/relebactam (IMI/REL = 96.9 %) and ceftazidime-avibactam (C/A = 97.0 %). MIC₅₀ and MIC₉₀ for C/T were 0.5 and 2 mg/L respectively against the 717 isolates. Among the 242 isolates (33.7 %) resistant to at least one anti-Pseudomonas β-lactam, close to 90 % were susceptible to C/T, C/A, MVB and IMI/REL. Among the 80 isolates resistant to piperacillin-tazobactam, cefepime and ceftazidime, 76.3 % were susceptible to C/T and only IMI/REL and amikacin reached susceptibility exceeding 80 %. Among the 32 isolates resistant to imipenem and meropenem, susceptibility exceeding 60 % was observed only for IMI/REL, C/T, and C/A. For these strains, the MIC₅₀ of C/T was 2 mg/L, while that of C/A was at the resistance threshold (8 mg/L). IMI/REL had the strongest activity (72 %) against the 25 isolates resistant to C/T. Lastly, 53 imipenem and/or C/T-R isolates harbored a class C β-lactam (blaPDC) variant, and one of them also carried the bla_PER-1 gene and another, the bla_VIM-2 gene.

CONCLUSION:

C/T is a reliable treatment option in RTI caused by P. aeruginosa.

01 May 2025·Journal of Global Antimicrobial Resistance

Whole-genome sequencing characterisation of a new KPC-245 variant-carrying Klebsiella pneumoniae strain isolated from a transplanted patient and resistant to ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam

Article

Author: Alessandra Mularoni ; Pier Giulio Conaldi ; Roberta Vazzana ; Nicola Cuscino ; Daniele Di Carlo ; Salvatore Castelbuono ; Andrea Cona ; Rita Minucci ; Francesco Monaco ; Claudia Vaiana ; Alessia Gallo

OBJECTIVE:

In recent decades, the increasing prevalence of multidrug-resistant Klebsiella pneumoniae carbapenemase (KPC)-carrying K. pneumoniae (KPC-Kp) has become a worldwide public concern. Herein, we characterised a ceftazidime/avibactam (CAZ/AVI), meropenem/vaborbactam (MER/VAB) and imipenem/relebactam (IMI/REL)-resistant KPC-Kp strain isolated from a critically ill transplant patient.

METHODS:

Antimicrobial susceptibility testing and whole-genome sequencing (WGS) were conducted to characterise the strain at phenotypic and genotypic levels. Genomic DNA was sequenced using the Illumina platform. Bioinformatic analyses were used to investigate the genome sequences both for resistance and virulence features, and for the characterisation of plasmids.

RESULTS:

Phenotypic characterisation revealed that the KPC-Kp isolate was highly resistant to a wide range of antibiotics, including all β-lactam/β-lactamase inhibitor combinations such as CAZ/AVI, MER/VAB, IMI/REL and cefiderocol. WGS analysis showed that the isolate, belonging to the rare lineage ST661, contained several resistance and virulence genes. Among the resistance genes, we identified a new KPC variant within the mobile genetic element Tn4401-KPC-245-characterised by the insertion of nine amino acids (RAPNKDDYT) at position 263 as well as an amino acid change within the protein sequence, E274D, compared with KPC-3. Interestingly, the presence of mutations only in the bla_KPC gene and not in other β-lactamase coding genes strongly points to the role of KPC-245 in β-lactam/β-lactamase inhibitor combinations and cefiderocol resistance.

CONCLUSIONS:

In our study, by using WGS analysis on a clinical isolate, we identified a new bla_KPC variant within the Tn4401 transposon. Our results confirm the importance of continuous surveillance of multidrug-resistant K. pneumoniae in the clinical context.

13

News (Medical) associated with Cilastatin Sodium/Imipenem/Relebactam

16 Jul 2026

·allsci.com

Shionogi seeking to expand Fetroja use into pediatric settings

Japan-based Shionogi & Co., Ltd. said the US FDA has accepted a Supplemental New Drug Application (sNDA) for cefiderocol (Fetroja), seeking to extend the antibiotic’s use to pediatric patients as young as 26 weeks of gestational age with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative organisms. The filing, submitted by the New Jersey arm of Shionogi, moves the Fetroja pediatric FDA approval process into formal review, with the FDA setting a PDUFA action date of February 23, 2027. Fetroja is currently approved in the US only for adults with these infections; the sNDA, if cleared, would make it one of the few novel antibiotics with a labeled indication for pediatric HABP/VABP. The filing addresses a gap that has persisted since cefiderocol’s 2019 approval. Companies developing antibiotics for multidrug-resistant Gram-negative bacterial infections treatment have historically prioritized adult registration trials, leaving clinicians to use these agents off-label in children based on extrapolated dosing. The World Health Organization flagged this gap explicitly, adding cefiderocol to its 2023 PAediatric Drug Optimization priority list, which identifies medicines urgently needed for children where dosing, safety, and formulation data are lacking. Pediatric serious infections caused by drug-resistant Gram-negative bacteria, including carbapenem-resistant Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa, present a narrower set of treatment options than in adults. Several newer beta-lactam/beta-lactamase inhibitor combinations, including ceftazidime-avibactam and ceftolozane-tazobactam, hold pediatric approvals for cUTI and complicated intra-abdominal infections but not for HABP/VABP. Others, such as imipenem-cilastatin-relebactam and meropenem-vaborbactam, remain restricted to adults across all indications. If the sNDA is cleared, cefiderocol would become one of the only novel antibiotics with a dedicated pediatric label covering hospital-acquired and ventilator-associated pneumonia, a niche where clinicians currently rely on carbapenems or off-label use of newer agents. Shionogi’s pursuit of this indication is also tied to broader government-backed antimicrobial resistance efforts. The expansion work is supported by an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) under Project BioShield, a program initially funded at $119 million with multiyear options worth up to $482 million. That contract also funds a US manufacturing site for Fetroja and work extending the antibiotic against biothreat pathogens including Burkholderia pseudomallei and Yersinia pestis, indicating the pediatric filing sits within a wider federal push to secure domestic supply of drugs effective against resistant and biothreat organisms. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Drug ApprovalQualified Infectious Disease Product

09 Jul 2026

·allsci.com

Cūrza backed by NIAID award for novel ribosomal inhibitor to combat multidrug-resistant infections

Curza Inc, a Salt Lake City-based antibiotic developer, has received a USD 1 million NIAID SBIR award to advance CZ-02, a novel class of oral antibiotics targeting multidrug-resistant Gram-negative pathogens — a bacterial threat for which no new oral antibiotic class has reached patients in over four decades. The R44 Direct Phase II grant, administered through the National Institute of Allergy and Infectious Diseases, funds late preclinical development of CZ-02 compounds designed to inhibit bacterial protein synthesis at a ribosomal binding site not targeted by any approved antibiotic. The natural product-inspired scaffold has been re-engineered to overcome the metabolic liabilities of its parent compound and to achieve activity against Gram-negative organisms, a class historically difficult to penetrate due to their outer membrane barrier. Preclinical data reported by the company indicate potency against MDR strains of Klebsiella pneumoniae and Escherichia coli in vitro and in vivo, with selectivity for bacterial over mammalian ribosomes and no observed mitochondrial toxicity. The funded work, led by principal investigator Charles A. Testa, pursues two parallel strategies to achieve oral bioavailability: formulation optimization and medicinal chemistry modification of physicochemical properties. In vivo pharmacokinetic studies and mouse models of septicemia, complicated urinary tract infection, and acute pyelonephritis will guide lead selection, with pharmacokinetic/pharmacodynamic profiling to define dosing parameters. The project is designed to deliver a single lead candidate ready for non-GLP toxicology and subsequent IND-enabling studies by grant completion in June 2027. The antimicrobial resistance space has attracted sustained NIH investment, but orally bioavailable agents active against MDR Gram-negatives remain a significant unmet need. Most recently approved Gram-negative antibiotics — including cefiderocol and imipenem-cilastatin-relebactam — are intravenous agents, limiting their utility in outpatient settings. Curza’s focus on oral delivery for cUTI and pyelonephritis indications addresses a clinically relevant gap, as these infections are among the most common drivers of MDR Gram-negative morbidity in community and hospital settings. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Qualified Infectious Disease Product

02 Dec 2024

·www.echemi.com

Merck's New Drug Approved! 15.9% Reduction in Pneumonia Mortality

On December 2, 2024, Merck's combination antibiotic injection, Imipenem/Cilastatin/Relebactam (containing 500mg imipenem, 500mg cilastatin, and 250mg relebactam), received marketing approval from China's National Medical Products Administration. Based on the latest advances in clinical trials, the approved indications may include ventilator-associated bacterial pneumonia (VABP) and hospital-acquired bacterial pneumonia (HABP). Imipenem/Cilastatin/Relebactam contains three active ingredients with different mechanisms of action: imipenem, a carbapenem antibiotic; relebactam, a β-lactamase inhibitor; and cilastatin, a membrane dipeptidase inhibitor. The drug was first approved in the U.S. in July 2019 under the trade name Recarbrio for treating adult patients with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) who have limited treatment options or no alternative therapies. In June 2020, the indications for this drug were expanded to include VABP and HABP. According to public records, Merck initiated a global Phase III clinical trial (N=478) for Imipenem/Cilastatin/Relebactam in September 2018 in the EU, Japan, and China. This trial aimed to evaluate the efficacy, safety, and tolerability of Imipenem/Cilastatin/Relebactam compared to Piperacillin/Tazobactam (produced by Pfizer) in treating patients with HABP and VABP. The primary endpoint of the study was all-cause mortality related to treatment by day 28. The study successfully concluded in July 2022. Results from the Phase III RESTORE-IMI 2 study conducted in the U.S., EU, and Japan indicated that Imipenem/Cilastatin/Relebactam could reduce all-cause mortality in patients with HABP and VABP by 15.9%, demonstrating non-inferiority to Piperacillin/Tazobactam (which reduced mortality by 21.3%). Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are common types of bacterial pneumonia among hospitalized patients. HABP refers to pneumonia that develops within 48 hours of hospitalization in patients who have not received invasive mechanical ventilation and are not in the latent phase of a pathogenic infection. VABP refers to pneumonia occurring in patients who have undergone intubation or tracheostomy and were mechanically ventilated for 48 hours, as well as pneumonia that arises within 48 hours after extubation or ventilator removal. Both types of pneumonia can lead to symptoms such as fever, chills, cough, chest pain, and increased oxygen demand.

Phase 3Drug ApprovalClinical ResultQualified Infectious Disease Product

100 Deals associated with Cilastatin Sodium/Imipenem/Relebactam

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Cilastatin Sodium/Imipenem/Relebactam	J01CR	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Infectious Diseases	Japan	MSD KK (Tokyo)	23 Jun 2021
Hospital acquired bacterial pneumonia	United States	Merck Sharp & Dohme Corp.	04 Jun 2020
Ventilator associated bacterial pneumonia	United States	Merck Sharp & Dohme Corp.	04 Jun 2020
Bacteremia	European Union	Merck Sharp & Dohme BV	13 Feb 2020
Bacteremia	Iceland	Merck Sharp & Dohme BV	13 Feb 2020
Bacteremia	Liechtenstein	Merck Sharp & Dohme BV	13 Feb 2020
Bacteremia	Norway	Merck Sharp & Dohme BV	13 Feb 2020
Hospital-acquired pneumonia	European Union	Merck Sharp & Dohme BV	13 Feb 2020
Hospital-acquired pneumonia	Iceland	Merck Sharp & Dohme BV	13 Feb 2020
Hospital-acquired pneumonia	Liechtenstein	Merck Sharp & Dohme BV	13 Feb 2020
Hospital-acquired pneumonia	Norway	Merck Sharp & Dohme BV	13 Feb 2020
Pneumonia, Ventilator-Associated	European Union	Merck Sharp & Dohme BV	13 Feb 2020
Pneumonia, Ventilator-Associated	Iceland	Merck Sharp & Dohme BV	13 Feb 2020
Pneumonia, Ventilator-Associated	Liechtenstein	Merck Sharp & Dohme BV	13 Feb 2020
Pneumonia, Ventilator-Associated	Norway	Merck Sharp & Dohme BV	13 Feb 2020
Complicated intra-abdominal infection	United States	Merck Sharp & Dohme Corp.	16 Jul 2019
Complicated urinary tract infection	United States	Merck Sharp & Dohme Corp.	16 Jul 2019
Gram-Negative Bacterial Infections	United States	Merck Sharp & Dohme Corp.	16 Jul 2019
Pyelonephritis	United States	Merck Sharp & Dohme Corp.	16 Jul 2019

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Carbapenem Resistant Bacterial Infection	Phase 3	-	Merck Sharp & Dohme LLC	21 Aug 2015
Febrile Neutropenia	Phase 2	United States	Merck Sharp & Dohme Corp.	14 Sep 2021
Hematologic Neoplasms	Phase 2	United States	Merck Sharp & Dohme Corp.	14 Sep 2021
Malignant Solid Neoplasm	Phase 2	United States	Merck Sharp & Dohme Corp.	14 Sep 2021
Sepsis	Phase 1	United States	Merck Sharp & Dohme Corp.	01 Jan 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03583333 (Phase III, Pubmed \| Int J Infect Dis)	Phase 3	Hospital acquired bacterial pneumonia \| Ventilator associated bacterial pneumonia	270	Imipenem/cilastatin/relebactam (IMI/REL)	pkcabcqkve(sdqcpbprhc) = Secondary outcomes were comparable between treatment groups, including favorable CR hwuvoruejd (unwbkskvka ) View more	Positive	01 Apr 2025
				Piperacillin/tazobactam (PIP/TAZ)
NCT04493151 (CTgov)	Phase 1	Sepsis	8	Imipenem, Cilastatin and Relebactam	ovydumgqwu(qxyaegzqea) = sdenuvqvcw snxscbezkq (taqpmnuvfr, 6.52) View more	-	07 Aug 2024
NCT04983901 (CTgov)	Phase 2	Malignant Solid Neoplasm \| Hematologic Neoplasms \| Febrile Neutropenia	100	Meropenem+Linezolid+Cefepime+Piperacillin-Tazobactam+Daptomycin+Vancomycin	iwceibdqmb(jjpageepym) = hlofwripga rnomohqhhs (rushhfezfp, znesczlgek - mfnacqwmws) View more	-	12 Mar 2024
NCT03230916 (7655A-020, Pubmed \| J Clin Pharmacol)	Phase 1	Gram-Negative Bacterial Infections	46	Imipenem/cilastatin/relebactam	imsdusncwu(kqgutrwbzo) = ylxihxysxk vqztodqlft (nbjyvhfkjj ) View more	-	10 Aug 2023
NCT03583333 (MK-7655A-016 \| 7655A-016 \| Phase III, CTgov)	Phase 3	Hospital acquired bacterial pneumonia \| Ventilator associated bacterial pneumonia	274	IMI/REL FDC+Linezolid (IMI/REL FDC)	yvyaethklm = oksnsrwwie lgpoovweks (prevhxgkgu, atahmuzvuc - jpdqkndgim) View more	-	28 Jun 2023
				Linezolid+PIP/TAZ FDC (PIP/TAZ FDC)	yvyaethklm = ekzyctwjls lgpoovweks (prevhxgkgu, achodvcqjv - gzspxilroo) View more
NCT02452047 (7655A-013 \| RESTORE-IMI 1, Pubmed \| Clin Infect Dis) Manual	Phase 3	Bacterial Infections	47	imipenem/relebactam	iwusmqxrva(bmmiopqdah) = qgsxlpggxq qnlactxdvx (kaxmzzyifl ) View more	Positive	15 Apr 2020
				imipenem+colistin	iwusmqxrva(bmmiopqdah) = dqsdotckxw qnlactxdvx (kaxmzzyifl ) View more
NCT03293485 (7655A-017, CTgov)	Phase 3	Complicated intra-abdominal infection \| Complicated urinary tract infection	83	imipenem+relebactam+cilastatin (cIAI/cUTI)	utxyxbydav = tmbyhprddo klkoziugqp (qkfbpyfgmh, bifwzzinwg - ppekcbwnbs) View more	-	17 Sep 2019
				imipenem+relebactam+cilastatin (cIAI)	vvpyfuvdhi = wobuumbcvh zymlajsyty (mwmemjulxg, juhqbojkcf - hjlbaeodrk) View more
NCT02452047 (7655A-013 \| RESTORE-IMI 1, CTgov)	Phase 3	Carbapenem Resistant Bacterial Infection	50	Placebo to CMS+Imipenem+Cilastatin/Relebactam (Group 1: Imipenem+Cilastatin/Relebactam)	eputqzewfm = lcbcotiwpl zcswhpdbvd (liifljvgan, jtqndyixzc - bxxvdaaeny) View more	-	19 Oct 2018
				Imipenem+Cilastatin+Colistimethate sodium (CMS) (Group 2: Colistimethate Sodium + Imipenem+Cilastatin)	eputqzewfm = ihnuejclay zcswhpdbvd (liifljvgan, oxpkjuyiiu - lhfwrlonws) View more